gip glp 1 agonist Understand GLP-1/GIP Dual Tirzepatide and Its Effect on Current Weight Loss Therapy Polyagonists Enable Increasingly Effective Treatment
Description
This narrative review examines the underlying pharmacology and clinical evidence behind the cardiovascular benefits of GLP-1 RAs, with particular focus on atherosclerotic cardiovascular disease
The study has several important caveats
Mishra R, Raj R, Elshimy G, et al
A secondary analysis of the STEP-HFpEF and STEP-HFpEF DM trials involving 1145 obese T2DM-associated HFpEF patients showed that semaglutide reduced NT-proBNP levels and improved health status after 52 weeks [83]
Rx-OTC Switches
